Wave Life Sciences（股票代码：WVE）今日盘中大涨13.39%，引起了市场的广泛关注。
消息面上，该公司公布了其肥胖症候选药物WVE-007的I期INLIGHT试验中期数据。数据显示，单次240mg皮下注射后12周，受试者的内脏脂肪减少9.4%，全身脂肪下降4.5%，瘦体重增加3.2%。此外，血清Activin E水平在43天时达到最大抑制78%，疗效维持超过85天，支持每年1-2次给药的潜力。
WVE-007采用了一种全新的RNA疗法机制，与传统的GLP-1受体激动剂不同，其“减脂不减肌”的效果直接解决了当前减肥药的最大痛点。这一积极数据增强了市场对Wave Life Sciences在肥胖症治疗领域潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.